Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $78.38

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have received an average recommendation of "Hold" from the nineteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $78.38.

CRSP has been the topic of a number of recent research reports. Barclays dropped their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 6th. Chardan Capital restated a "buy" rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research note on Monday, December 30th. Bank of America cut their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP lifted its holdings in CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock worth $39,608,000 after buying an additional 743,075 shares in the last quarter. State Street Corp boosted its position in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Farallon Capital Management LLC acquired a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at $28,625,000. Marshall Wace LLP purchased a new stake in CRISPR Therapeutics during the 2nd quarter worth $10,078,000. Finally, KBC Group NV increased its position in shares of CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock worth $2,382,000 after acquiring an additional 57,696 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Trading Up 6.4 %

NASDAQ:CRSP traded up $2.68 on Wednesday, reaching $44.19. 4,465,328 shares of the stock traded hands, compared to its average volume of 1,952,238. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of -15.63 and a beta of 1.68. The company's 50 day moving average is $44.72 and its 200-day moving average is $47.99. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter last year, the firm posted ($1.41) earnings per share. On average, equities research analysts forecast that CRISPR Therapeutics will post -5.13 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.